Ray Therapeutics, Inc.

Ray Therapeutics is pleased to welcome Vikas Sinha, MBA, to our Board of Directors and named Chair of the Audit Committee.    A seasoned biopharma leader, Vikas brings decades of experience guiding companies from clinical development to commercial success. His leadership comes at a pivotal time for RayTx following our $125M Series B and key regulatory designations. We look forward to his partnership as we advance our mission to restore vision for patients living with retinal degenerative diseases. https://lnkd.in/ed6Vu7Aj

At Ray Therapeutics, we recognize that the caliber of our team is the foundation of everything we build. We have assembled a group of accomplished scientists, clinicians, and business professionals united by a shared sense of urgency to develop therapies that can meaningfully change the lives of patients living with blinding retinal diseases. We are committed to fostering an environment where exceptional talent is empowered to do their best work, and where purpose drives every decision. Explore career opportunities at Ray: https://lnkd.in/eQuGT-fy

Central vision is how we read a book, recognize a face, and watch a child grow up. For people living with Stargardt's disease, an inherited retinal degeneration that can manifest in childhood or adolescence, that vision fades. Estimated to impact 1 in 17,000 people worldwide, it's a disease with no effective treatments today. During Stargardt Disease Awareness Week, we're reminded of the urgency behind the science. Gene therapy and optogenetics are changing what's possible — and what patients can hope for. This week and every week, we stand with the Stargardt community. Learn more: https://lnkd.in/eBiuDYWi

We're excited to welcome Kimberly Stewart to Ray Therapeutics as an Executive Assistant. Kim brings over 15 years of experience supporting senior leaders across biotech and pharmaceutical organizations, most recently at 89bio. Based in the Bay Area, she'll be a key liaison to our leadership team, keeping operations running seamlessly as we continue to grow. Glad to have you on the team, Kim!

Every year, the Association for Research in Vision and Ophthalmology (ARVO) brings together the brightest minds in vision science, and 2026 was no exception. For the millions living with blinding retinal diseases like retinitis pigmentosa, Stargardt disease, and geographic atrophy, the research being presented this week in Denver represents something profound: hope backed by science. These are conditions that have long been considered untreatable. The conversations happening at ARVO, across gene therapy, optogenetics, regenerative medicine, and beyond, are changing that narrative. The future of vision restoration is being written right now. We're proud to be part of it.

The question at the center of Eyecelerator Association for Research in Vision and Ophthalmology (ARVO) 2026 this week: Is vision improvement on the horizon for regenerative medicine? Our Chief Medical & Scientific Officer, Peter Francis, MD PhD, joined the panel to explore where the science stands, and where it's headed. Patients are waiting. The field is moving. And the answers are getting closer.

We're thrilled to welcome Hannah Hershoff, MD, PhD, to Ray Therapeutics as Vice President, Clinical Development & Medical Affairs. An ophthalmologist with 20+ years of drug development experience, spanning small molecules, topical therapies, and AAV gene therapy, Hannah has held senior leadership roles at Lassen Therapeutics, AiViva BioPharma, Longwood Pharmaceuticals, and the Novartis Institutes for BioMedical Research. She holds a Post-Doctoral Fellowship from Harvard Medical School and is an inventor and author of 20+ patents and publications in ophthalmology and neurology. We're grateful to have her expertise and vision on our team. Welcome, Hannah!

Today, Ray Therapeutics was granted Priority Medicines (PRIME) Designation by the European Medicines Agency (EMA) for RTx-015, our lead program in Retinitis Pigmentosa.   PRIME designation is reserved for medicines that offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options. For the RP community, where treatment options remain critically limited, this recognition underscores both the promise of RTx-015 and the deep need that continues to drive our work.   We're appreciative of the patients, clinicians, and researchers who have championed this work alongside us, and we stay fully committed to making the promise of RTx-015 a reality.   Read the full announcement: https://lnkd.in/ebp4YYy9

The human eye is remarkably sophisticated, which makes restoring vision a complex endeavor. Visual optogenetics offers a compelling scientific approach to address this. By introducing channelrhodopsins into surviving retinal neurons, light entering the eye can once again stimulate those cells, generating signals that are transmitted through the optic nerve to the brain, where vision is perceived. It is a field grounded in decades of foundational neuroscience and gaining momentum in clinical trials that show benefit for patients with few or no treatment options. Learn more: https://lnkd.in/etdt23E6

Thank you, Susan B. Nichols, for sharing this milestone with your network. The enthusiasm and support from our community means everything as we work toward restoring vision for patients with inherited retinal diseases.